173 related articles for article (PubMed ID: 37449937)
1. Children's Oncology Group's 2023 blueprint for research: Epidemiology.
Lupo PJ; Marcotte EL; Scheurer ME; Poynter JN; Spector LG;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30566. PubMed ID: 37449937
[TBL] [Abstract][Full Text] [Related]
2. Children's Oncology Group's 2023 blueprint for research: Bone tumors.
Reed DR; Grohar P; Rubin E; Binitie O; Krailo M; Davis J; DuBois SG; Janeway KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30583. PubMed ID: 37501549
[TBL] [Abstract][Full Text] [Related]
3. Children's Oncology Group's 2013 blueprint for research: bone tumors.
Gorlick R; Janeway K; Lessnick S; Randall RL; Marina N;
Pediatr Blood Cancer; 2013 Jun; 60(6):1009-15. PubMed ID: 23255238
[TBL] [Abstract][Full Text] [Related]
4. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee.
Meyer JS; Nadel HR; Marina N; Womer RB; Brown KL; Eary JF; Gorlick R; Grier HE; Randall RL; Lawlor ER; Lessnick SL; Schomberg PJ; Kailo MD
Pediatr Blood Cancer; 2008 Aug; 51(2):163-70. PubMed ID: 18454470
[TBL] [Abstract][Full Text] [Related]
5. Children's Oncology Group's 2023 blueprint for research: Young investigators.
Esbenshade AJ; Kahalley LS; Wistinghausen B; Cash T; Baertschiger RM; Zarnegar-Lumley S; Green A; Dhall G;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30567. PubMed ID: 37438856
[TBL] [Abstract][Full Text] [Related]
6. Children's Oncology Group's 2013 blueprint for research: epidemiology.
Spector LG; Ross JA; Olshan AF;
Pediatr Blood Cancer; 2013 Jun; 60(6):1059-62. PubMed ID: 23255344
[TBL] [Abstract][Full Text] [Related]
7. Children's Oncology Group's 2023 blueprint for research: Diversity and health disparities.
Winestone LE; Beauchemin MP; Bona K; Kahn J; Prasad P; Robles JM; Velez MC;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30592. PubMed ID: 37501542
[TBL] [Abstract][Full Text] [Related]
8. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
Chen I; Pasalic D; Fischer-Valuck B; Frangoul H; DeWees T; Shinohara ET; Perkins SM
Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
[TBL] [Abstract][Full Text] [Related]
9. The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer.
Breneman JC; Donaldson SS; Constine L; Merchant T; Marcus K; Paulino AC; Followill D; Mahajan A; Laack N; Esiashvili N; Haas-Kogan D; Laurie F; Olch A; Ulin K; Hodgson D; Yock TI; Terezakis S; Krasin M; Panoff J; Chuba P; Hua CH; Hess CB; Houghton PJ; Wolden S; Buchsbaum J; Fitzgerald TJ; Kalapurakal JA
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):860-874. PubMed ID: 29976498
[TBL] [Abstract][Full Text] [Related]
10. Seasonal variations in the diagnosis of childhood cancer in the United States.
Ross JA; Severson RK; Swensen AR; Pollock BH; Gurney JG; Robison LL
Br J Cancer; 1999 Oct; 81(3):549-53. PubMed ID: 10507784
[TBL] [Abstract][Full Text] [Related]
11. Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.
Bhuta R; Shah R; Gell JJ; Poynter JN; Bagrodia A; Dicken BJ; Pashankar F; Frazier AL; Shaikh F
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30562. PubMed ID: 37449938
[TBL] [Abstract][Full Text] [Related]
12. Children's Oncology Group's 2023 blueprint for research: Rare tumors.
Schultz KAP; Chintagumpala M; Piao J; Chen KS; Gartrell R; Christison-Lagay E; Berry JL; Shah R; Laetsch TW;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30574. PubMed ID: 37458616
[TBL] [Abstract][Full Text] [Related]
13. Children's Oncology Group 2023 blueprint: Nursing discipline.
Zupanec S; Herriage T; Landier W;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30575. PubMed ID: 37470719
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Treatment of Pediatric Bone Sarcomas.
Grohar PJ; Janeway KA; Mase LD; Schiffman JD
Am Soc Clin Oncol Educ Book; 2017; 37():725-735. PubMed ID: 28561686
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies.
Malempati S; Hawkins DS
Pediatr Blood Cancer; 2012 Jul; 59(1):5-10. PubMed ID: 22378628
[TBL] [Abstract][Full Text] [Related]
16. Children's Oncology Group's 2023 blueprint for research: Behavioral science.
Embry L; Bingen K; Conklin HM; Hardy S; Jacola LM; Marchak JG; Paltin I; Pelletier W; Devine KA
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30557. PubMed ID: 37430416
[TBL] [Abstract][Full Text] [Related]
17. An exploratory study of environmental and medical factors potentially related to childhood cancer.
Schwartzbaum JA; George SL; Pratt CB; Davis B
Med Pediatr Oncol; 1991; 19(2):115-21. PubMed ID: 1849220
[TBL] [Abstract][Full Text] [Related]
18. Children's Oncology Group's 2023 blueprint for research: Pharmacy.
Ostrenga AR; Thackray J; McLearan HH; Mulieri KM; Bisaccia E; Militano O; Dupuis LL; Bernhardt MB;
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30581. PubMed ID: 37460409
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma.
Dickens DS; Kozielski R; Leavey PJ; Timmons C; Cripe TP
J Pediatr Hematol Oncol; 2003 Apr; 25(4):282-5. PubMed ID: 12679640
[TBL] [Abstract][Full Text] [Related]
20. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.
Glover J; Man TK; Barkauskas DA; Hall D; Tello T; Sullivan MB; Gorlick R; Janeway K; Grier H; Lau C; Toretsky JA; Borinstein SC; Khanna C; Fan TM;
PLoS One; 2017; 12(7):e0181204. PubMed ID: 28732082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
